Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer — MAPS  

IPMN Clinical Trial

Official title: Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer

Status Recruiting

Clinical Trial Summary

Pancreatic cancer is the 5th leading cause of cancer death in Australia. Surgery remains the most effective treatment for early pancreatic cancer and currently the only potential for cure. Unfortunately, many patients present with advanced disease and are not suitable for surgery. Therefore, it is vital to detect these cancers early. In the absence of significant data from prospective studies, all of the guidelines are based on a critical review of available data and consensus of experts. The primary aim is to delineate the progression of IPMN to pancreatic malignancy as confirmed by surgical pathology, radiology and biochemical diagnosis. The secondary aims are (i) To outline the management of IPMNs for those who have progressed straight to surgery or surveillance by endoscopic ultrasound (EUS) (ii)To validate the International consensus guidelines for management of IPMN - Fukuoka consensus guidelines and tertiary aim to identify potential risk factors, if any that increase risk of malignancy within the IPMNs.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• IPMN
• IPMN, Pancreatic
• Neoplasms
• Neoplasms, Cystic, Mucinous, and Serous

• NCT number: NCT05117723
• Study type: Observational [Patient Registry]
• Source: St Vincent's Hospital Melbourne
• Contact: Lynn Chong
• Phone: +61 3 9231 2074
• Email: lynn.chong@svha.org.au
• Status: Recruiting
• Start date: August 26, 2021
• Completion date: July 2031